Log In
Print
BCIQ
Print
Print this Print this
 

TOL-3021 (formerly BHT-3021, RG7426)

  Manage Alerts
Collapse Summary General Information
Company Tolerion Inc.
DescriptionVaccine containing an engineered DNA plasmid encoding proinsulin
Molecular Target Not available
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$325.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today